Max Kozlov

Effective Sept. 1, Sutton, 55, will succeed John Fischer, 64, as the head of the Fortune 500 company. Fischer, who has led Clayton-based Olin for four years, will become executive chairman of the $1.9 billion company.

The clinical trial, published Thursday in the New England Journal of Medicine, show that the drug, tofersen, lowers levels of a harmful protein in patients who have a mutation to the SOD1 gene. This mutation, present in about 2% of people with ALS, causes patients to produce an abnormally high amount of the protein.

View all

Get up-to-the-minute news sent straight to your device.


News Alerts

Blues News

Breaking News

Cardinals News

Daily 6

National Breaking News